BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33305268)

  • 1. HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis.
    Erickson AW; Ghodrati F; Habbous S; Jerzak KJ; Sahgal A; Ahluwalia MS; Das S
    Neurooncol Adv; 2020; 2(1):vdaa136. PubMed ID: 33305268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis.
    Erickson AW; Habbous S; Hoey C; Jerzak KJ; Das S
    NPJ Breast Cancer; 2021 Feb; 7(1):17. PubMed ID: 33602948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis.
    Erickson AW; Brastianos PK; Das S
    JAMA Netw Open; 2020 Mar; 3(3):e201617. PubMed ID: 32211870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
    Erickson AW; Habbous S; Wright F; Lofters AK; Jerzak KJ; Das S
    JAMA Oncol; 2021 Aug; 7(8):1220-1224. PubMed ID: 34081080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Brain Metastases With Survival in Patients With Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis.
    Li AY; Gaebe K; Zulfiqar A; Lee G; Jerzak KJ; Sahgal A; Habbous S; Erickson AW; Das S
    JAMA Netw Open; 2023 Feb; 6(2):e230475. PubMed ID: 36821113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer.
    Korner EJ; Morris A; Allen IE; Hurvitz S; Beattie MS; Kalesan B
    Syst Rev; 2015 Oct; 4():133. PubMed ID: 26428301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
    Dai Q; Wang Y; Liao M; Chen H
    Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
    Tian T; Ye J; Zhou S
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis.
    Wang Y; Xu H; Han Y; Wu Y; Sa Q; Wang J
    ESMO Open; 2023 Jun; 8(3):101216. PubMed ID: 37084609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
    Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
    Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
    Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
    ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
    Koleva-Kolarova RG; Oktora MP; Robijn AL; Greuter MJW; Reyners AKL; Buskens E; de Bock GH
    Cancer Treat Rev; 2017 Apr; 55():16-25. PubMed ID: 28288388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
    Gaebe K; Li AY; Park A; Parmar A; Lok BH; Sahgal A; Chan KKW; Erickson AW; Das S
    Lancet Oncol; 2022 Jul; 23(7):931-939. PubMed ID: 35644163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy with
    Zhu J; Min N; Chen Y; Li X
    Ann Transl Med; 2023 Mar; 11(5):200. PubMed ID: 37007556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.